Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Pancreatic Stent Placement to Prevent Pancreatitis After ERCP-GPC
NCT07495111Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2025
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Randomised, open-label trial in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Proportion of Patients with Post-ERCP Pancreatitis at 72 hours. Started Dec 2025; status: recruiting.
02
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT07495111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07495111.